Mankind Pharma Ltd: Stock Analysis & Fundamentals

Updated this week

Mankind Pharma Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 45.3. ROE: 14.7%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

👔Promoter stake down 2.2% this quarter

🏛️DII accumulation — stake up 2.0%

Key Numbers

Current Price

₹2,039

Dividend Yield

0.05%

Market Cap

84.2K Cr

Valuation

N/A

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd

Strong • 4w streak

+15.9%

Torrent Pharmaceuticals Ltd

Average • 12w streak

+23.4%

Dr Reddys Laboratories Ltd

Zydus Lifesciences Ltd

Weak

+10.0%

← Back to Pharma - Formulators Dashboard

Frequently Asked Questions: Mankind Pharma Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Mankind Pharma Ltd's latest quarterly results?

Mankind Pharma Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: +7.5%
Revenue Growth YoY: +11.5%
Operating Margin: 26.0%

What is Mankind Pharma Ltd's current PE ratio?

Mankind Pharma Ltd's current PE ratio is 45.3x.

Current PE: 45.3x
Market Cap: 84.2K Cr
Dividend Yield: 0.05%

What is Mankind Pharma Ltd's price-to-book ratio?

Mankind Pharma Ltd's price-to-book ratio is 5.5x.

Price-to-Book (P/B): 5.5x
Book Value per Share: ₹370
Current Price: ₹2039

Is Mankind Pharma Ltd a fundamentally strong company?

Mankind Pharma Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 16.0%

Is Mankind Pharma Ltd debt free?

Mankind Pharma Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹9,000 Cr

What is Mankind Pharma Ltd's return on equity (ROE) and ROCE?

Mankind Pharma Ltd's return ratios over recent years

FY2023: ROCE 22.0%
FY2024: ROCE 26.0%
FY2025: ROCE 16.0%

Is Mankind Pharma Ltd's cash flow positive?

Mankind Pharma Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹2,000 Cr
Free Cash Flow (FCF): ₹-10,000 Cr
CFO/PAT Ratio: 120% (strong cash conversion)

What is Mankind Pharma Ltd's dividend yield?

Mankind Pharma Ltd's current dividend yield is 0.05%.

Dividend Yield: 0.05%
Current Price: ₹2039

Who holds Mankind Pharma Ltd shares — promoters, FII, DII?

Mankind Pharma Ltd's shareholding pattern (Dec 2025)

Promoters: 72.7%
FII (Foreign): 11.3%
DII (Domestic): 13.3%
Public: 2.8%

Is promoter holding increasing or decreasing in Mankind Pharma Ltd?

Mankind Pharma Ltd's promoter holding has decreased recently.

Current Promoter Holding: 72.7% (Dec 2025)
Previous Quarter: 72.7% (Sep 2025)
Change: -0.01% (decreasing — worth monitoring)

Is Mankind Pharma Ltd a new momentum entry or an established outperformer?

Mankind Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Mankind Pharma Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Mankind Pharma Ltd may be worth studying

Cash flow is positive — CFO ₹2,000 Cr

What is the investment thesis for Mankind Pharma Ltd?

Mankind Pharma Ltd investment thesis summary:

What is the future outlook for Mankind Pharma Ltd?

Mankind Pharma Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.